NTGX – 10 : An Oral Gold
Therapeutically renowned and traditionally trusted compound, optimized and enhanced for multiple applications by patented process. Potential segmentation / positioning areas :
– Diabetic Retinopathy
– Anti-Ageing, Immunity Booster, Cardio Protective
Why Gold ?
Gold is perhaps the most anciently administered medicine known to humans and we are successfully using gold in variety of health segments including their prevention and their cure. The current endeavor is to harvest the best results from these segments and present them in a scientifically prudent way for global acceptance.
Current Focus Area
Diabetic Retinopathy :
Diabetic Retinopathy affects up to 80 % of those who have had Diabetes for 20 years or more. At least 90% of new cases could be reduced with proper treatment and monitoring of the eyes.
The longer a person has diabetes, the higher his or her chances of developing Diabetic Retinopathy.
Diabetic retinopathy is the result of damage to the small blood vessels and neurons of the retina.
Current State of Development
- Recently completed Pilot Clinical Trial on patients of Diabetic Retinopathy with very encouraging results.
- Currently, under process of Ph II/III submission to DCGI for Diabetic Retinopathy.
Other Potential Applications
- Anti – Ageing
Gold Nanoparticles have effects on increasing activity of enzymes which are known to be scavengers of Free Radicals posing as an excellent compound in treating diseases related to Ageing and Degeneration. Also it can be used in reducing the effect of Ageing on various body systems.
- Immunity Booster
Nano Gold has shown to be beneficial in eliciting protective immune mechanism and also in Modulating Immune response in treating Auto immune arthritis.
- Cardio-Protective
Gold is well known and used since centuries to prevent and treat Cardiac Disorders.
NTGX-10
(ORAL GOLD FORMULATION)
Diabetic Retinopathy – The most common complication of diabetes and a major cause of blindness globally – 90 million patients are diagnosed worldwide with ~ 15 million paties just in India.
Unique Value Proposition
- IP Protections of the Key AI.
- First every oral drung availabe for Eye disease including diabetic retinopathy.
- No need for request clinic visit for injections.
- Safety and effective in patients established.
Limitations of Current Therapy
- Only two lines of treatments available (1st Anti-VEGF and 2nd Corticosteraids).
- Both these treatments are given as injections in the eye with lot of complications.
- High cost of currently preferred anti-VEGF injections, with 150% patients showing resistance.
Opportunity
Potential of NTGX-10 to change the treatment paradigm of Diabetic Retinopathy due to the following key reasons :
- No Oral Therapy avialable.
- No treatments available if patient develop resistance to current therapies.
- Patients without frequest accessibility to retina specalists for injections in eye often do not get regular treatment.